Michel M. van den Heuvel - Researcher Profile

Publications

3 shown

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Leora Horn , Martin Steins , Enriqueta Felip +26 more

Nivolumab was not associated with significantly longer progression-free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD...

2017 New England Journal of Medicine 2526 citations

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Solange Peters , Scott Gettinger , Melissa L. Johnson +25 more

Purpose BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti–programmed death-ligand 1 (PD-L1) monoclonal antibody, in advanced non–small-cell lung cance...

2017 Journal of Clinical Oncology 412 citations

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Sanjay Popat , Joachim Diebold , Joshua K. Sabari +35 more

2019 Annals of Oncology 1292 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 4,230
Institution: The Netherlands Cancer Institute

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-6372-2153

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.